Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Other

Institut National De La Recherche Agronomique

The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center

Universités Paris 6 Et Paris 7

Université Pierre Et Marie Curie

Arieh Gertler

Isabelle Callebaut

Eran Elinav

Zamir Halpern

Radha Krishna

Jean Djiane

Leptin muteins, in particular leptin antagonists, with increased binding affinity to leptin receptor are provided. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of any disorder in which a non-desirable or deleterious activity of endogenous leptin or an altered innate immune response is implicated.

High affinity leptins and leptin antagonists

The present invention provides compositions and methods relating to avian leptin receptor binding domains. The present invention demonstrates that these compositions are useful for detecting the presence of leptin in a sample and distinguishing free leptin from bound leptin in multiple species. Methods and kits are presented for determining free leptin in a sample from an individual by assaying a sample for the binding of leptin to an avian leptin receptor binding domain, and detecting the bound leptin by using a labeled anti-leptin antibody.

Leptin binding domain compositions and methods thereto

The invention relates to synthetic leptin antagonists in which at least two amino acid residues of the sequence LDFI/S of the hydrophobic binding site at positions-of a leptin polypeptide sequence are substituted with different amino acid residues such that the site becomes less hydrophobic, and fragments of said leptin antagonists.

Leptin antagonists

Growing community of inventors

Rehovot, Israel

Arieh Gertler